DrugPatentWatch Database Preview
Join the DrugPatentWatch Referral Program Get access to a free drug patent landscape report or a free one-month subscription
« Back to Dashboard
RAF-265 is an investigational drug.
There have been 219 clinical trials for RAF-265. The most recent clinical trial was a Phase 3 trial, which was initiated on January 1st 2014.
The most common disease conditions in clinical trials are Melanoma, Colorectal Neoplasms, and Carcinoma. The leading clinical trial sponsors are National Cancer Institute (NCI), Bayer, and Novartis Pharmaceuticals.
There are thirty-nine US patents protecting this investigational drug and six hundred and ten international patents.
Recent Clinical Trials for RAF-265
|Safety of ABM-1310 Monotherapy in Patients With Advanced Solid Tumors||ABM Therapeutics, Inc.||Phase 1|
|Cetuximab as Salvage Therapy in Patients With Neo Wild-type RAS/RAF Metastatic Colorectal Cancer With Liver Metastases.||GCS IHFB Cognacq-Jay||Phase 2|
|A Trial of Dabrafenib, Trametinib and Hydroxychloroquine for Patients With Recurrent LGG or HGG With a BRAF Aberration||Pediatric Brain Tumor Consortium||Phase 1/Phase 2|
Top disease conditions for RAF-265
Top clinical trial sponsors for RAF-265
|Drugname||Patent Number||Patent Title||Patent Assignee||Estimated Expiration|
|RAF-265||Start Trial||Low, immune enhancing, dose mtor inhibitors and uses thereof||Novartis AG (Basel, CH)||Start Trial|
|RAF-265||Start Trial||Nucleic acid encoding a humanized anti-BCMA chimeric antigen receptor||Novartis AG (Basel, CH) The Trustees of the University of Pennsylvania (Philadelphia, PA)||Start Trial|
|RAF-265||Start Trial||Formylated N-heterocyclic derivatives as FGFR4 inhibitors||NOVARTIS AG (Basel, CH)||Start Trial|
|RAF-265||Start Trial||Methods of treating hemoglobinopathies||Duke University (Durham, NC)||Start Trial|
|RAF-265||Start Trial||Triazolopyrimidine compounds and uses thereof||Novartis AG (Basel, CH)||Start Trial|
|>Drugname||>Patent Number||>Patent Title||>Patent Assignee||>Estimated Expiration|
|Drugname||Country||Document Number||Estimated Expiration||Related US Patent|
|RAF-265||Eurasian Patent Organization||201690987||2033-11-13||Start Trial|
|>Drugname||>Country||>Document Number||>Estimated Expiration||>Related US Patent|